METHYLPREDNISOLONE

Post-LOE

methylprednisolone

R-Pharm US

ANDAORALTABLET

Approved

Apr 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

METHYLPREDNISOLONE (methylprednisolone) by R-Pharm US is corticosteroid hormone receptor agonists [moa]. Approved for the following conditions: 1. First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Indications (1)

the following conditions: 1

Clinical Trials (20)

NCT07353749Phase 4Not Yet Recruiting

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Started Jan 2026

864 enrolled

Unruptured Intracranial AneurysmsCerebrovascular EventHemorrhagic Stroke+2 more

NCT07101445Phase 4Recruiting

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Started Sep 2025

94 enrolled

Multiple Myeloma

NCT06623370Phase 4Completed

The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group

Started Oct 2024

NCT05532072Phase 1Unknown

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

Started Sep 2022

140 enrolled

Graves Ophthalmopathy

NCT04016025Phase 4Completed

A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers

Started Dec 2020

80 enrolled

Adherence, PatientChronic Eczema

Worked on METHYLPREDNISOLONE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.